An Update on the Treatment of Hemangiomas in Children With Interferon Alfa-2a
Open Access
- 1 January 1999
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Otolaryngology–Head & Neck Surgery
- Vol. 125 (1) , 21-27
- https://doi.org/10.1001/archotol.125.1.21
Abstract
HEMANGIOMAS are the most common head and neck tumors diagnosed in pediatric patients, affecting nearly 10% of white children and 22 % of premature infants.1,2 These vascular lesions preferentially affect girls by a 3:1 margin. Initially appearing as an erythematous macular region, hemangiomas enter a proliferative phase and may grow to a relatively large size. After reaching a growth plateau in early childhood, spontaneous regression is the rule, with 50% of lesions resolving by 5 years of age and 70% by 7 years of age.3Keywords
This publication has 17 references indexed in Scilit:
- Inflammatory bowel disease and predisposition to osteopeniaArchives of Disease in Childhood, 1997
- The Use of Interferon Alfa-2a for Life-Threatening HemangiomasJAMA Otolaryngology–Head & Neck Surgery, 1995
- Interferon Alfa-2A Therapy for Airway HemangiomasAnnals of Otology, Rhinology & Laryngology, 1994
- Hemangiomas and Vascular Malformations of Infancy and ChildhoodPediatric Clinics of North America, 1993
- Interferon Alfa-2a Therapy for Life-Threatening Hemangiomas of InfancyNew England Journal of Medicine, 1992
- Biological classification of soft-tissue vascular anomalies: MR correlation.American Journal of Roentgenology, 1991
- Complex Hemangiomas of Infants and ChildrenArchives of Surgery, 1990
- Treatment of Pulmonary Hemangiomatosis with Recombinant Interferon Alfa-2aNew England Journal of Medicine, 1989
- Intralesional Corticosteroid Therapy for Infantile HemangiomasPlastic and Reconstructive Surgery, 1989
- Strawberry Hemangioma in Preterm InfantsPediatric Dermatology, 1986